m6A-modified circRNA MYO1C participates in the tumor immune surveillance of pancreatic ductal adenocarcinoma through m6A/PD-L1 manner
暂无分享,去创建一个
Weihua Luo | Mingfei Li | Kun Tian | Hua Guan
[1] Quanbo Zhou,et al. circCUL2 induces an inflammatory CAF phenotype in pancreatic ductal adenocarcinoma via the activation of the MyD88-dependent NF-κB signaling pathway , 2022, Journal of experimental & clinical cancer research : CR.
[2] Janel L. Kopp,et al. Cell Type of Pancreatic Ductal Adenocarcinoma Origin: Implications for Prognosis and Clinical Outcomes , 2021, Visceral Medicine.
[3] L. de Geus-Oei,et al. Molecular Targeted Positron Emission Tomography Imaging and Radionuclide Therapy of Pancreatic Ductal Adenocarcinoma , 2021, Cancers.
[4] Rahul Peravali,et al. The Relationship between Acute and Chronic Pancreatitis with Pancreatic Adenocarcinoma: Review , 2021, Diseases.
[5] W. El-Deiry,et al. Therapeutic Targeting of Autophagy in Pancreatic Ductal Adenocarcinoma , 2021, Frontiers in Pharmacology.
[6] Zhi-wen Zhang,et al. RNA m6A Demethylase ALKBH5 Protects Against Pancreatic Ductal Adenocarcinoma via Targeting Regulators of Iron Metabolism , 2021, Frontiers in Cell and Developmental Biology.
[7] Xiao‐Yu Yin,et al. HNRNPC impedes m6A-dependent anti-metastatic alternative splicing events in pancreatic ductal adenocarcinoma. , 2021, Cancer letters.
[8] C. Hwang,et al. Epigenetic Alterations in Pancreatic Cancer Metastasis , 2021, Biomolecules.
[9] Prosenjit Paul,et al. Circular RNAs in cancer and diabetes , 2021, Journal of Genetics.
[10] O. Thorlacius-Ussing,et al. Cell-Free DNA Methylation as Blood-Based Biomarkers for Pancreatic Adenocarcinoma—A Literature Update , 2021, Epigenomes.
[11] W. Yuan,et al. N6-methyladenosine-induced circ1662 promotes metastasis of colorectal cancer by accelerating YAP1 nuclear localization , 2021, Theranostics.
[12] G. Shan,et al. CircRNA in cancer: Fundamental mechanism and clinical potential. , 2021, Cancer letters.
[13] Wenxin Qin,et al. circNDUFB2 inhibits non-small cell lung cancer progression via destabilizing IGF2BPs and activating anti-tumor immunity , 2021, Nature communications.
[14] Kefei Yuan,et al. Circular RNA circDLC1 inhibits MMP1-mediated liver cancer progression via interaction with HuR , 2020, Theranostics.
[15] Chaofeng Hou,et al. The role of N6-methyladenosine (m6A) modification in the regulation of circRNAs , 2020, Molecular Cancer.
[16] Xuan Du,et al. Identification and characterization of tumorigenic circular RNAs in cervical cancer. , 2020, Cellular signalling.
[17] S. Banerjee,et al. Differential methylation landscape of pancreatic ductal adenocarcinoma and its precancerous lesions. , 2020, Hepatobiliary & pancreatic diseases international : HBPD INT.
[18] Jie-Wei Chen,et al. N6-methyladenosine modification of circNSUN2 facilitates cytoplasmic export and stabilizes HMGA2 to promote colorectal liver metastasis , 2019, Nature Communications.
[19] Tianxin Lin,et al. Circular RNA ACVR2A suppresses bladder cancer cells proliferation and metastasis through miR-626/EYA4 axis , 2019, Molecular Cancer.
[20] Yi Xing,et al. Genome-Wide Maps of m6A circRNAs Identify Widespread and Cell-Type-Specific Methylation Patterns that Are Distinct from mRNAs. , 2017, Cell reports.
[21] Feng Liu,et al. METTL14 suppresses the metastatic potential of hepatocellular carcinoma by modulating N6‐methyladenosine‐dependent primary MicroRNA processing , 2017, Hepatology.
[22] S. Hüttelmaier,et al. Subcellular localization and RNP formation of IGF2BPs (IGF2 mRNA-binding proteins) is modulated by distinct RNA-binding domains , 2013, Biological chemistry.
[23] M. Lederer,et al. Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression? , 2012, Cellular and Molecular Life Sciences.